HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/5/2016)... YORK (PRWEB) , ... May 05, 2016 , ... TIME ... swimming safety – today announced a new partnership to reach nearly 1 million children ... happen in an instant and is the leading cause of accidental death in children ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Jennifer Drago presented a talk highlighting the organization’s successful Care Transitions ... Chicago. , The talk was titled “Minimizing Costs in the Post-Acute Environment Through ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer Camp will ... with his university coaching staff. Together they bring their winning Vandals coaching philosophy to ... youth players ages 5-13, and high school players. Session dates are as follows: , ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs (TTL) ... the eve of National Nurses Week (May 6-12). Currently, HireNurses is a ... their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically expand ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Collection Bureau, Inc. ... Clark brings more than 15 years of experience within the healthcare revenue cycle industry. ... career as the Director of Patient Financial Services at Spectrum Health. While at Spectrum ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016 Research and Markets has ... Imaging in the USA"  report to their offering.  ,     ... on the current Positron Emission Tomography (PET) scanner and ... market. Along with the current known number of ... , the report also contains a detailed breakdown ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Systemic Lupus ... 2016"  report to their offering.  ... The latest research Europe Systemic Lupus ... 2016, provides comprehensive insights into Systemic Lupus ...
(Date:5/4/2016)... NEW YORK , May 4, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 - ... End User (Hospital, Diagnostic Center and Others)" by P&S Market ... at $4,894.3 million in 2015, and it is expected to ... slice type, the high slice type segment is expected to ...
Breaking Medicine Technology:
Cached News: